In the EMPA-REG OUTCOME (Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients) trial, the sodium-glucose cotransporter-2 (SGLT2) inhibitor empagliflozin reduced the risk of incident or worsening nephropathy by 39%, and the composite kidney outcome of doubling of serum creatinine, initiation of renal replacement therapy or death due to kidney disease by 46% versus placebo in patients with type 2 diabetes (T2D) and established cardiovascular disease [1]. This evidence concerns the gene SLC5A2 and cardiovascular disorder.